Pharmeuropa Chapter 2.1.7. Balances for Analytical Purposes published for Comments
Recommendation

Monday, 21 September 2026 14.00 - 16.00 h
Regulatory Landscape: ECHA, USP, Pharmacopoeias and FDA Enforcement
In the Pharmeuropa issue 37.1, a proposal for a revised chapter 2.1.7. Balances for analytical purposes has been published for public consultation.
The revised chapter, like the current version, focuses exclusively on balances used for analytical purposes, excluding those used in manufacturing or other applications.
The draft introduces definitions for two types of balances, multi-interval and multiple range balances, distinguished by how their capacity is segmented. The new definitions are as follows:
- "Multi-interval balance: balance having one weighing range divided into partial ranges, each with different scale intervals d; when tared after a load has been applied, the balance returns to the finest range, i.e. the weighing range with the smallest scale interval d."
- "Multiple range balance: balance having more than one weighing range, each with different scale intervals d; when tared after a load has been applied, the balance remains in the weighing range that refers to the load value applied."
Additionally, the revision includes updates to technical terminology related to equipment performance. Among other clarifications, the following sentence has been added:
- "Calibrations and performance checks must be carried out under conditions that accurately represent the routine operating conditions of the balance."
The section on minimum weight has also been expanded to provide further guidance.
The complete draft, along with detailed information on the revisions, is available on the Pharmeuropa website (registration required). Comments can be submitted until 31 March 2025.
Related GMP News
03.09.2026USP Article: Supporting the Detection of Asbestos in Pharmaceutical Talc
02.09.2026USP Publishes Comments Received on Chapter <320>
26.08.2026New USP Requirements for Asbestos Testing in Pharmaceutical Talc
19.08.2026FDA Warning Letter: Averaging Data to Override OOS Findings
12.08.2026ECA's Analytical Control Group Publishes Detailed Report on OOS Survey
12.08.2026BP Publishes Key Insights on Limits in Chromatographic Tests


